MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 74 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.59 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $45,000 | 0.0% | 10,735 | 0.0% | 0.00% | – |
| Q1 2019 | $45,000 | +45.2% | 10,735 | 0.0% | 0.00% | – |
| Q4 2018 | $31,000 | -71.0% | 10,735 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $107,000 | +40.8% | 10,735 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $76,000 | +85.4% | 10,735 | 0.0% | 0.00% | – |
| Q1 2018 | $41,000 | -53.4% | 10,735 | 0.0% | 0.00% | -100.0% |
| Q4 2017 | $88,000 | +25.7% | 10,735 | -10.6% | 0.00% | 0.0% |
| Q3 2017 | $70,000 | -95.9% | 12,007 | -98.7% | 0.00% | -96.8% |
| Q3 2016 | $1,715,000 | +130.2% | 942,059 | +60.5% | 0.03% | +106.7% |
| Q2 2016 | $745,000 | -83.9% | 586,780 | -31.7% | 0.02% | -85.4% |
| Q1 2016 | $4,621,000 | -28.7% | 858,961 | +1.3% | 0.10% | -41.8% |
| Q4 2015 | $6,481,000 | +185.0% | 848,236 | +211.0% | 0.18% | +185.5% |
| Q3 2015 | $2,274,000 | -7.8% | 272,701 | +28.2% | 0.06% | +3.3% |
| Q2 2015 | $2,467,000 | – | 212,642 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 3,977,453 | $15,194,000 | 8.96% |
| Granite Point Capital Management, L.P. | 2,638,321 | $10,078,000 | 0.98% |
| New Leaf Venture Partners, L.L.C. | 342,550 | $1,309,000 | 0.71% |
| 683 Capital Management, LLC | 1,200,000 | $4,584,000 | 0.40% |
| Virtus ETF Advisers LLC | 80,389 | $307,000 | 0.27% |
| Iguana Healthcare Management, LLC | 100,000 | $382,000 | 0.25% |
| THREE BAYS CAPITAL LP | 944,300 | $3,607,000 | 0.25% |
| Granite Point Capital Management, L.P. | 549,900 | $2,101,000 | 0.20% |
| Cormorant Asset Management, LP | 478,111 | $1,826,000 | 0.14% |
| GMT CAPITAL CORP | 2,533,798 | $9,680,000 | 0.12% |